| Cytochrome P4502C9: an enzyme of major importance in human drug metabolism JO Miners, DJ Birkett British journal of clinical pharmacology 45 (6), 525-538, 1998 | 1152 | 1998 |
| Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily PI Mackenzie, KW Bock, B Burchell, C Guillemette, S Ikushiro, T Iyanagi, ... Pharmacogenetics and genomics 15 (10), 677-685, 2005 | 984 | 2005 |
| The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism TH Sullivan-Klose, BI Ghanayem, DA Bell, ZY Zhang, LS Kaminsky, ... Pharmacogenetics and Genomics 6 (4), 341-349, 1996 | 829 | 1996 |
| The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification A Rowland, JO Miners, PI Mackenzie The international journal of biochemistry & cell biology 45 (6), 1121-1132, 2013 | 751 | 2013 |
| Drug glucuronidation in humans JO Miners, PI Mackenzie Pharmacology & therapeutics 51 (3), 347-369, 1991 | 467 | 1991 |
| Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. W Tassaneeyakul, DJ Birkett, ME Veronese, ME McManus, RH Tukey, ... The Journal of pharmacology and experimental therapeutics 265 (1), 401-407, 1993 | 415 | 1993 |
| Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by … V Uchaipichat, PI Mackenzie, XH Guo, D Gardner-Stephen, A Galetin, ... Drug metabolism and disposition 32 (4), 413-423, 2004 | 384 | 2004 |
| The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation R Drew, JO Miners Biochemical pharmacology 33 (19), 2989-2994, 1984 | 332 | 1984 |
| Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance CR Bhasker, W McKinnon, A Stone, ACT Lo, T Kubota, T Ishizaki, ... Pharmacogenetics and Genomics 10 (8), 679-685, 2000 | 297 | 2000 |
| Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non–small cell lung cancer G Kichenadasse, JO Miners, AA Mangoni, A Rowland, AM Hopkins, ... JAMA oncology 6 (4), 512-518, 2020 | 290 | 2020 |
| Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance JO Miners, RA McKinnon, PI Mackenzie Toxicology 181, 453-456, 2002 | 284 | 2002 |
| Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. C Jin, JO Miners, KJ Lillywhite, PI Mackenzie The Journal of pharmacology and experimental therapeutics 264 (1), 475-479, 1993 | 273 | 1993 |
| Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism T ANDERSSON, JO MINERS, ME VERONESE, W Tassaneeyakul, ... British journal of clinical pharmacology 36 (6), 521-530, 1993 | 272 | 1993 |
| In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises JO Miners, KM Knights, JB Houston, PI Mackenzie Biochemical pharmacology 71 (11), 1531-1539, 2006 | 271 | 2006 |
| In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction A Rowland, DJ Elliot, JA Williams, PI Mackenzie, RG Dickinson, ... Drug Metabolism and Disposition 34 (6), 1055-1062, 2006 | 269 | 2006 |
| Diazepam metabolism by human liver microsomes is mediated by both S‐mephenytoin hydroxylase and CYP3A isoforms. T Andersson, JO Miners, ME Veronese, DJ Birkett British journal of clinical pharmacology 38 (2), 131-137, 1994 | 269 | 1994 |
| Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9 ME Veronese, PI Mackenzie, CJ Doecke, ME McManus, JO Miners, ... Biochemical and biophysical research communications 175 (3), 1112-1118, 1991 | 269 | 1991 |
| Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone)“probes … V Uchaipichat, PI Mackenzie, DJ Elliot, JO Miners Drug Metabolism and Disposition 34 (3), 449-456, 2006 | 268 | 2006 |
| The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro … JO Miners, PI Mackenzie, KM Knights Drug metabolism reviews 42 (1), 196-208, 2010 | 262 | 2010 |
| Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches JO Miners, PA Smith, MJ Sorich, RA McKinnon, PI Mackenzie Annu. Rev. Pharmacol. Toxicol. 44 (1), 1-25, 2004 | 254 | 2004 |
